Elutia (ELUT) Price/OCF Ratio: History & Chart

Elutia Inc(ELUT)

Biotechnology · Gaithersburg, MD

$0.80-0.02 (-2.14%)

Delayed quote: Oct 6, 2026, 11:39 AM EDT

About Elutia Inc

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Gaithersburg, MD

26 employees

elutia.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: C. Randal Mills

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Elutia Inc (ELUT)	$35.54M	N/A	N/A	N/A	N/A
QT Imaging Holdings, Inc. (QTI)vs ›	$35.80M	N/A	N/A	N/A	N/A
DocGo Inc. (DCGO)vs ›	$35.78M	N/A	2.00	3.35	33.77
Elicio Therapeutics, Inc. (ELTX)vs ›	$36.80M	N/A	N/A	N/A	N/A
Edesa Biotech, Inc. (EDSA)vs ›	$37.28M	N/A	N/A	N/A	N/A
BriaCell Therapeutics Corp. (BCTX)vs ›	$35.15M	N/A	N/A	N/A	N/A
Accuray Incorporated (ARAY)vs ›	$34.48M	N/A	17.67	45.36	32.48
Grace Therapeutics, Inc. (GRCE)vs ›	$34.34M	N/A	N/A	N/A	N/A
Incannex Healthcare Limited (IXHL)vs ›	$38.35M	N/A	N/A	N/A	N/A
Aligos Therapeutics, Inc. (ALGS)vs ›	$33.23M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Elutia Inc (ELUT)

$35.54M

N/A

QT Imaging Holdings, Inc. (QTI)vs ›

$35.80M

N/A

DocGo Inc. (DCGO)vs ›

$35.78M

N/A

2.00

3.35

33.77

Elicio Therapeutics, Inc. (ELTX)vs ›

$36.80M

N/A

Edesa Biotech, Inc. (EDSA)vs ›

$37.28M

N/A

BriaCell Therapeutics Corp. (BCTX)vs ›

$35.15M

N/A

Accuray Incorporated (ARAY)vs ›

$34.48M

N/A

17.67

45.36

32.48

Grace Therapeutics, Inc. (GRCE)vs ›

$34.34M

N/A

Incannex Healthcare Limited (IXHL)vs ›

$38.35M

N/A

Aligos Therapeutics, Inc. (ALGS)vs ›

$33.23M

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

ELUT Price/OCF Ratio Metrics

ELUT Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics